Suzanne Bruhn
Director/Board Member presso MIND MEDICINE (MINDMED) INC.
Patrimonio netto: 759 167 $ in data 31/03/2024
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Ivana Magovcevic-Liebisch | M | 55 | 6 anni | |
| Gregg Lapointe | M | 65 |
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 10 anni |
| Timothy Walbert | M | 57 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 13 anni |
| Schond Greenway | M | 52 | 3 anni | |
| Chris Cline | M | 40 | 10 anni | |
| Ho Young Huh | M | 54 | 7 anni | |
| Carol Vallone | F | 67 | 3 anni | |
| Gary Lyons | M | 73 | 10 anni | |
| Richard Jack | M | - |
Promedior, Inc.
 Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | 10 anni |
| Eric Dube | M | 51 | 5 anni | |
| Jeffrey Meckler | M | 57 | 10 anni | |
| Bernard Coulie | M | 58 | 8 anni | |
| Robert Barrow | M | - | 3 anni | |
| Miri Wernli | M | 71 | 4 anni | |
| Smital Shah | F | 48 | 5 anni | |
| Sandra E. Poole | F | 60 | 5 anni | |
| Stefan Vitorovic | M | 39 | 3 anni | |
| Barbara Tate | M | - |
Tiaki Therapeutics, Inc.
 Tiaki Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tiaki Therapeutics, Inc. develops novel therapeutics for Alzheimer's disease. The company was founded by Barbara Tate and is headquartered in Cambridge, MA. | - |
| David Pyott | M | 70 | 3 anni | |
| Bill DeGrado | M | - | 9 anni | |
| Samantha Haeberlein | M | - | 1 anni | |
| John Curnutte | M | 72 | 7 anni | |
| Katharine Knobil | M | 60 | 2 anni | |
| Mike Ouimette | M | 51 | 4 anni | |
| Gerhard Koenig | M | 63 | 4 anni | |
| Sandra Calvin | F | 59 | 10 anni | |
| Carole Abel | F | - | - | |
| Mary Jeka | F | - |
EMPath
 EMPath Miscellaneous Commercial ServicesCommercial Services EMPath provides nonprofit programs for women. The non-profit company is based in Boston, MA. | 14 anni |
| Roger Crystal | M | 47 | 2 anni | |
| Darren Cline | M | 59 | 1 anni | |
| Mark Sullivan | M | 52 | 1 anni | |
| Elizabeth Reed | F | 53 | 7 anni | |
| Mary Thistle | F | 64 | 2 anni | |
| Cheryl Blanchard | M | 59 | 4 anni | |
| Tim Coughlin | M | 57 | 9 anni | |
| Andreas Krebs | M | 66 | 3 anni | |
| June Almenoff | M | 67 | 3 anni | |
| Gilla Kaplan | M | 76 | 4 anni | |
| Gayle Crowell | F | 73 | 4 anni | |
| Monica Sandberg | M | - | 5 anni | |
| Christopher Keenan | M | - | 4 anni | |
| Ruth Williams-Brinkley | F | 72 | 3 anni | |
| Roy Baynes | M | 69 | 8 anni | |
| Bruce Booth | M | 49 | 4 anni | |
| Kim Lee | M | - | 10 anni | |
| Paul Hoelscher | M | 59 | 8 anni | |
| John Orwin | M | 59 | 7 anni | |
| Ron Squarer | M | 57 | 7 anni | |
| Thomas McCourt | M | 66 | 1 anni | |
| Rik Derynck | M | - | - | |
| Kevin Durfee | M | - | - | |
| Kelly Neelon | M | - | - | |
| Park Guo | M | - | - | |
| Peter Mack | M | - | 3 anni | |
| Katerina Leftheris | F | - | - | |
| Casey H. Logan | M | 52 | 6 anni | |
| Daniel Karlin | M | 44 | 3 anni | |
| Peter Heerma | M | 53 | 5 anni | |
| Jennifer Ziolkowski | F | 50 | 4 anni | |
| Hal Chapman | M | - | 9 anni | |
| Dean Sheppard | M | - | 9 anni | |
| Naomi Eichenbaum | F | - | - | |
| Hans Hull | M | 49 | 8 anni | |
| Bill Rote | M | 61 | 7 anni | |
| Pam Meneses | F | - | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Christopher Starr | M | 71 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 10 anni |
| Georgia Erbez | F | 57 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 2 anni |
| Stephen Aselage | M | 73 | 10 anni | |
| Uli Alf Hacksell | M | 74 | 5 anni | |
| Julie Smith | F | 53 | - | |
| Graham Hetherington | M | 65 | 6 anni | |
| Franz Hefti | M | 76 |
Proclara Biosciences, Inc.
 Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | 3 anni |
| Michael Patrick Smith | M | 55 | 1 anni | |
| Kim Tsuchimoto | F | 61 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 9 anni |
| Simon Pedder | M | 63 | 2 anni | |
| Dominick Colangelo | M | 60 |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | 4 anni |
| Susan Kilsby | F | 65 | 8 anni | |
| Llew Keltner | M | 74 | 7 anni | |
| James Bowling | M | 56 | 10 anni | |
| Angus Russell | M | 68 | 14 anni | |
| Vijay Samant | M | 77 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 3 anni |
| Michael Dennis Price | M | 66 | 3 anni | |
| Jason Lettmann | M | 46 |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | 6 anni |
| Jeffrey Poulton | M | 56 | 14 anni | |
| Erich Sager | M | 66 | 6 anni | |
| Sol Barer | M | 76 | 1 anni | |
| Gregory Perry | M | 63 | 1 anni | |
| Cortney Caudill | F | - | 4 anni | |
| Phillip Gutry | M | 50 | 6 anni | |
| Souheil Salah | M | - | 16 anni | |
| Maxim Jacobs | M | - | - | |
| Illya Keith Maher | M | 56 | 1 anni | |
| Tatjana Anni Hilde May | F | 58 | - | |
| Paul McBarron | M | 63 | 5 anni | |
| Cynthia Hu | M | 54 | 2 anni | |
| V. Lawlis | M | 72 | 5 anni | |
| Brigid Makes | F | 68 | 4 anni | |
| Charles Homcy | M | 75 | 7 anni | |
| Keith W. Schmidt | M | 74 | 1 anni | |
| Ian Karp | M | - | 5 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 89 | 89.00% |
| Irlanda | 9 | 9.00% |
| Canada | 2 | 2.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Suzanne Bruhn
- Contatti personali
